Slide 1: Next-generation assistive technology and data measurement
For personal use only Next-generation assistive technology and data measurement TECHKNOW PRESENTATION JEREMY STEELE, CEO 31 JULY 2024 CONTROLBIONICS.COM | ASX:CBL
Slide 2: Disclaimer
Disclaimer This presentation is intended to provide a general outline only and is not intended to be a definitive statement on the subject matter covered in it. The For personal use only information in this presentation, whether written or verbal, has been prepared without taking into account the co
Slide 3: On the cusp of rapid global growth
INTRODUCTION On the cusp of rapid global growth For personal use only A proven medical device company with sizeable global sales of core products that we design and manufacture Long history of Regulatory Core business Blue sky and Many levers for Near cash flow expertise with our clearance and conti
Slide 4: EMG technology: the heart of our solutions
INTRODUCTION EMG technology: the heart of our solutions For personal use only
Slide 5: EMG technology: how it works
INTRODUCTION EMG technology: how it works For personal use only An EMG signal is Our patented code detected. creates a “switch” to operate devices Your brain sends a To move your finger, Our core IP uses smart Users can type, generate thought like “move my an electrical signal is algorithms to detec
Slide 6: Markets
Markets For personal use only Assistive Communication Assistive Mobility Data Measurement
Slide 7: Assistive Communication: Our fastest near term path to growth
ASSISTIVE COMMUNICATION Our fastest near term path to growth For personal use only What Is It Works like a switch that turns into a mouse click, letting the user control their Potential Catalyst: communication and software In August we find out if we secure a Market Size Minimum $1.3bn globally new
Slide 8: Assistive Mobility: The world's first autonomous wheelchair
ASSISTIVE MOBILITY The world’s first autonomous wheelchair For personal use only What Is It A patent-pending module, developed with Deakin University, retrofits powered wheelchairs for safer, independent home travel controlled by the user's intentions Market Size Minimum $100m globally Current sales
Slide 9: The new NeuroStrip is a game-changer
BEYOND ASSISTIVE TECHNOLOGY The new NeuroStrip is a game-changer For personal use only
Slide 10: NeuroStrip: Blue sky potential with endless uses
BEYOND ASSISTIVE TECHNOLOGY NEUROSTRIP Blue sky potential with endless uses Market strategy: For personal use only Enter those with the fastest, lowest- What Is It A world-first all-in-one accelerometer and EMG device that measures physiological cost access with data like unintentional muscle moveme
Slide 11: Gaining traction
FINANCIALS Gaining traction REVENUE (A$ m) EBITDA ($A m) 25% year on year For personal use only • 300 systems sold in our key markets in FY23. • FY23 revenue up an impressive 25% over FY22. • US is the strongest market as the strength of our team and time in-market delivers. EMPLOYEES % SALES • Stro
Slide 12: Experienced leadership
PEOPLE Experienced leadership Jeremy Steele For personal use only BOARD Proven senior finance and accounting professional with more than 20 years of extensive experience in accounting, auditing and financial analysis with both Chartered Accountant (CAANZ) and Certified Public Shannon Boothroyd Accou
Slide 13: Get in touch
Get in touch For personal use only COMPANY INVESTOR RELATIONS JEREMY STEELE JOE DURAK CEO EXECUTIVE DIRECTOR & FOUNDER CONTROL BIONICS LYNX ADVISORS jsteele@controlbionics.com joe@lynxadvisors.com.au +61 433 229 470 +61 414 465 582 CONTROLBIONICS.COM | ASX:CBL